Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Ovarian Cancer Recurrent × Paclitaxel × Clear all

Phase

Status

Sponsor Class

INDUSTRY 2 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 272 Carcinoma, Non-Small-Cell Lung 158 Ovarian Neoplasms 136 Lung Neoplasms 79 Esophageal Neoplasms 70 Stomach Neoplasms 67 Triple Negative Breast Neoplasms 62 Fallopian Tube Neoplasms 58 Squamous Cell Carcinoma of Head and Neck 45 Esophageal Squamous Cell Carcinoma 45 Neoplasm Metastasis 41 Neoplasms 40 Carcinoma, Ovarian Epithelial 40 Head and Neck Neoplasms 38 Endometrial Neoplasms 35 Uterine Cervical Neoplasms 26 Recurrence 23 Carcinoma, Squamous Cell 22 Adenocarcinoma Of Esophagus 21 Prostatic Neoplasms 19 Urinary Bladder Neoplasms 17 Inflammatory Breast Neoplasms 17 Melanoma 16 Unspecified Adult Solid Tumor, Protocol Specific 14 Breast Neoplasms, Male 14 Adenocarcinoma of Lung 14 Carcinoma 13 Testicular Neoplasms 11 Pancreatic Neoplasms 11 Lymphoma 11

Interventions

poly(I).poly(c12,U) 1 pembrolizumab 1 mirabegron 1 liposomal doxorubicin 1 disitamab vedotin 1 apatinib 1 anlotinib 1 Tocotrienols 1 Platinum Compounds 1 Paclitaxel 1 Lenalidomide 1 Interferon alpha-2 1 Hyperthermic Intraperitoneal Chemotherapy 1 Cisplatin 1 Carboplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04072263 2021-04-01

OVACURE

Leiden University Medical Center

Phase 1/2 Unknown

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡